ALOX5 and arthritic joint disease: Since LTB4 has been demonstrated to be a key regulator in the pathogenesis of murine arthritis [9], it may be conceivable that targeting the 5-LO pathway could provide additional benefits in the treatment of RA, by reducing the formation of LTB4 and, by this means, decreasing the chemotaxis of inflammatory cells.